Replies to post #15744 on GTC Biotherapeutics (fka GTCB)

[DragonBits]

bp, if number 1 is right, why would Genzyme let this technology slip through their fingers and be sold to LFB for $15 million? That is the key question, all other issues are secondary.

Secondary issues.

The malaria vaccine, what stage of testing is that in? Does anyone know if it works at all?

It's not as simple as milking a goat, there is a complex filter process and genetic drift.

...................................

The assumption is that the industry is working on more efficient methods of producing the needed proteins. That and the industry is working on ehancements to proteins. Otherwise there would be more interest in funding GTC.

As to what exactly the process might be, why no interest in GTC, maybe call up Genzyme and keep asking questions of their scientists, maybe one will be talkative and tell you what they think. Call up others do the same, like Elan.

Otherwise sooner or later the reasons for the neglect of GTC will become obvious. Or maybe GTC will suddely blossom.

[vinmantoo]

Biopearl,

As usual JohnBits is speaking out his butt with no real knowledge. GTCB's transgenic methodology is being used to make proteins that cannot be made in significant quanties or economically by traditional methods, which is the shift in GTCB's strategy to plasma proteins and BCE by pharmathene. The issue of MAbs is distinct, and is where GTCB ran into real resisitance.

I am still amused by JohBits saying it might be better to know less about a company and its science when making investment decisions. That is all you need to know about him and his opinions. He doesn't know much but feels the urgent need to continually keep tell us about GTCB.